Arcus Biosciences to Participate in the 2018 Wedbush PacGrow Healthcare Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Aug 1, 2018--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 2:30 pm ET at the Parker New York, in New York City, NY.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is being evaluated in combination with other agents in multiple tumor types in a Phase 1/1b program, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and will be tested in combination with Arcus’s other product candidates. Arcus’s other programs include an anti-TIGIT antibody AB154, which is in a phase 1 program, and a small molecule inhibitor of CD73 AB680, which is in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. For more information about Arcus Biosciences, please visit www.arcusbio.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180801005722/en/
CONTACT: Arcus Biosciences
Jennifer Jarrett, 510-694-6261
Nicole Arndt, 510-284-4728
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL
SOURCE: Arcus Biosciences
Copyright Business Wire 2018.
PUB: 08/01/2018 04:05 PM/DISC: 08/01/2018 04:06 PM